Veradermics, Inc. director and 10% owner Patrick G. Enright reported indirect conversions and purchases of common stock. On February 5, 2026, Series B and Series C Convertible Preferred Stock automatically converted into 1,236,631 and 1,171,121 shares of common stock, respectively, on a 10.067-for-1 basis immediately before the closing of the company’s initial public offering, with no additional consideration.
Entities affiliated with Enright then bought 192,647 and 882,353 common shares at $17 per share, held through Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P., where voting and investment power is shared and beneficial ownership is disclaimed beyond pecuniary interests. On February 3, 2026, Enright also received a direct stock option for 45,131 shares at a $17 exercise price, vesting in full on February 3, 2027.
Veradermics, Inc. reported that its General Counsel, Michael V. Greco, received a grant of stock options on February 3, 2026. The award covers 144,401 stock options with an exercise price of $17 per share, held as direct beneficial ownership.
According to the vesting terms, 25% of the options vest on February 3, 2027, the first anniversary of the vesting commencement date. The remaining options vest in equal monthly installments over the following 36 months, contingent on continued service with the company.
Veradermics, Inc. reported that officer Mark Neumann, its Chief Commercial Officer and Strategy Officer, received a grant of stock options on February 3, 2026. The award covers 102,885 stock options with an exercise price of $17 per share.
According to the vesting terms, 25% of the underlying common shares vest on February 3, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. After this grant, Neumann directly holds 102,885 derivative securities.
Carrano Dominic Gabriel reported acquisition or exercise transactions in a Form 4 filing for MANE. The filing lists transactions totaling 148,011 shares. Following the reported transactions, holdings were 148,011 shares.
Veradermics, Inc. Chief Technical Officer Timothy August Durso reported stock-based transactions and updated his holdings. On February 3, 2026, he received a stock option grant for 213,352 shares of common stock at an exercise price of $17 per share. The option vests 25% on February 3, 2027, with the remaining shares vesting in equal monthly installments over 36 months, subject to continued service.
On February 5, 2026, 1,473 shares of Series A Convertible Preferred Stock automatically converted to 1,473 shares of common stock on a 10.067-for-1 basis without additional payment, immediately before the company’s initial public offering. After these transactions, Durso directly held 118,190 common shares and had an option over 213,352 shares, and 116,717 common shares were held indirectly by the Durso Family Trust. The trust is for the benefit of his children, is administered by his spouse as trustee, and Durso disclaims beneficial ownership of those trust-held shares.
Veradermics, Inc. Chief Executive Officer and director Reid Alexander Waldman reported insider equity changes. On February 5, 2026, 1,437 shares of Series A Convertible Preferred Stock automatically converted into 1,437 shares of common stock on a 10.067-for-1 basis, bringing his directly held common stock to 234,872 shares.
Separately, on February 3, 2026, he was granted a stock option for 556,399 shares of common stock at an exercise price of $17 per share. The option vests 25% on February 3, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.
Veradermics, Incorporated updated its corporate charter and bylaws on February 5, 2026 in connection with the consummation of its initial public offering of common stock. A fifth restated certificate of incorporation became effective upon filing with the Delaware Secretary of State.
The Restated Certificate authorizes 200 million shares of common stock and 25 million shares of undesignated preferred stock, eliminates all prior preferred series, and removes stockholders’ ability to act by written consent. Amended and restated bylaws also took effect, refining stockholder proposal and director nomination procedures, updating director and officer indemnification, and aligning with the new charter provisions.